These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 312667)

  • 1. Comparison of factor VIII-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate.
    Weinstein M; Deykin D
    Blood; 1979 Jun; 53(6):1095-105. PubMed ID: 312667
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure - function relationship of factor VIII/von Willebrand factor. Application to the study of variant von Willebrand's disease and cryosupernatant prepared from normal plasma.
    Pietu G; Obert B; Larrieu MJ; Meyer D
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):671-85. PubMed ID: 6777898
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity.
    Martin SE; Marder VJ; Francis CW; Loftus LS; Barlow GH
    Blood; 1980 May; 55(5):848-58. PubMed ID: 6767513
    [No Abstract]   [Full Text] [Related]  

  • 4. Dispersity of human factor VIII--Von Willebrand factor.
    van Mourik JA; Bolhuis PA
    Thromb Res; 1978 Jul; 13(1):15-24. PubMed ID: 308712
    [No Abstract]   [Full Text] [Related]  

  • 5. Porcine factor VIII:C prepared by affinity interaction with von Willebrand factor and heterologous antibodies: sodium dodecyl sulfate polyacrylamide gel analysis.
    Knutson GJ; Fass DN
    Blood; 1982 Mar; 59(3):615-24. PubMed ID: 6800420
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of factor VIII/von Willebrand factor protein (F VIII/vWF) and F VIII/vWF-poor cryoprecipitate on post-ischemic microvascular reperfusion in the central nervous system.
    Hallenbeck JM; Furlow TW; Gralnick HR
    Stroke; 1981; 12(1):93-7. PubMed ID: 6784287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.
    Meyer D; Obert B; Pietu G; Lavergne JM; Zimmerman TS
    J Lab Clin Med; 1980 Apr; 95(4):590-602. PubMed ID: 6965697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of molecular size of factor VIII/von Willebrand factor in von Willbrand's disease.
    Mikami S; Takahashi Y; Nishino M; Okubo Y; Fukui H
    Thromb Haemost; 1981 Jun; 45(3):272-5. PubMed ID: 6792740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of a therapeutic concentrate of factor VIII/vWf prepared in a closed system].
    Mazurier C; Maillard J; Parquet-Gernez A; Goudemand M
    Rev Fr Transfus Immunohematol; 1982 Feb; 25(1):25-43. PubMed ID: 6803339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand's disease: combined qualitative and quantitative abnormalities.
    Gralnick HR; Sultan Y; Coller BS
    N Engl J Med; 1977 May; 296(18):1024-30. PubMed ID: 300468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement therapy in platelet-type von Willebrand disease.
    Takahashi H
    Am J Hematol; 1985 Apr; 18(4):351-62. PubMed ID: 3919572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy.
    Mannucci PM; Ruggeri ZM; Ciavarella N; Kazatchkine MD; Mowbray JF
    Blood; 1981 Jan; 57(1):25-31. PubMed ID: 6778538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.
    Ruggeri ZM; Zimmerman TS
    J Clin Invest; 1980 Jun; 65(6):1318-25. PubMed ID: 6773982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmin digestion of factor VIII: characterization of the breakdown products with respect to antigenicity and von Willebrand activity.
    Guisasola JA; Cockburn CG; Hardisty RM
    Thromb Haemost; 1978 Oct; 40(2):302-15. PubMed ID: 153594
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of succinylation and dodecyl, succinylation on bovine factor VIII/von Willebrand factor complex.
    Thuy LP; Brown JE; Baugh RF; Hougie C
    Thromb Res; 1980 May 1-15; 18(3-4):305-13. PubMed ID: 6774433
    [No Abstract]   [Full Text] [Related]  

  • 16. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate.
    Burnouf-Radosevich M; Burnouf T
    Vox Sang; 1992; 62(1):1-11. PubMed ID: 1580062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.
    Mazurier C; Samor B; Deromeuf C; Goudemand M
    Thromb Res; 1985 Mar; 37(6):651-8. PubMed ID: 3922084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen.
    Santoro SA
    Biochim Biophys Acta; 1983 Mar; 756(1):123-6. PubMed ID: 6402037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type IIB von Willebrand's disease: unusual response to cryoprecipitate infusion.
    Weinger RS; Cimo PL; Moake JL; Olson JD; Heller MS
    Ann Intern Med; 1981 Jan; 94(1):47-50. PubMed ID: 6778284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.